Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Reduced expression of CYLD in human colon and hepatocellular carcinomas

In English

Författare

  • Claus Hellerbrand
  • Elisabeth Bumes
  • Frauke Bataille
  • Wolfgang Dietmaier
  • Ramin Massoumi
  • Anja K Bosserhoff

Summary, in English

CYLD was originally identified as a tumor suppressor that is mutated in familial cylindromatosis. Recent studies suggested a role for CYLD in nuclear factor-kappaB (NF-kappaB) regulation. NF-kappaB activation has been connected with multiple aspects of oncogenesis but the underlying molecular mechanisms of persistent NF-kappaB activation in tumors remain largely unknown. Thus, we evaluated CYLD transcription in different colon and hepatocellular carcinoma cell lines and tissue samples, respectively. CYLD was downregulated or lost in all tumor cell lines investigated as compared with primary human colonic epithelial cells and hepatocytes, respectively. Further, quantitative PCR analysis revealed reduced CYLD mRNA expression in most tumor samples compared with non-tumorous tissue. Analysis on protein level confirmed these findings. Functional assays with CYLD transfected cell lines revealed that CYLD expression decreased NF-kappaB activity. Thus, functional relevant loss of CYLD expression may contribute to tumor development and progression, and may provide a new target for therapeutic strategies.

Publiceringsår

2007

Språk

Engelska

Sidor

21-27

Publikation/Tidskrift/Serie

Carcinogenesis

Volym

28

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Oxford University Press

Ämne

  • Cancer and Oncology

Status

Published

Forskningsgrupp

  • Cell Pathology, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 0143-3334